Global Antifungal Drugs Market to Grow at 4% CAGR from 2021-2026
The global antifungal drugs market has exhibited moderate growth from 2015-2020, driven by increasing prevalence of fungal and nosocomial infections. According to a report, the market is expected to grow at a compound annual growth rate (CAGR) of around 4% from 2021-2026. The market is driven by the convenient availability of over-the-counter (OTC) drugs, rising health consciousness among the masses, and product innovations such as synthetic and semi-synthetic azole-based compounds.
Key Takeaways:
- The global antifungal drugs market is expected to grow at a CAGR of 4% from 2021-2026.
- The market has exhibited moderate growth from 2015-2020, driven by increasing prevalence of fungal and nosocomial infections.
- Antifungal drugs, such as polyenes, azoles, and allylamines, are used for the treatment of fungal infections on skin, hair, and nails.
- The market is driven by the convenient availability of OTC drugs in both urban and rural areas.
- The report mentions companies such as Abbott Laboratories, Astellas Pharma, and Bayer AG as key players in the market.
- The market is segmented by drug class, including polyenes, azoles, and allylamines, and by indication, including athlete's foot, ringworm, and candidiasis.
- The report also mentions the impact of COVID-19 on the market and the growth-inducing factors, such as product innovations and R&D investments.
Statistics:
- CAGR of the global antifungal drugs market: 4% (2021-2026)
- Market growth from 2015-2020: moderate
- Share of OTC drugs in the market: significant
- Number of key players mentioned: 7
- Number of companies mentioned: 14
- Market segmentation by drug class: polyenes, azoles, and allylamines
- Market segmentation by indication: athlete's foot, ringworm, and candidiasis
Sources:
- "The 'Antifungal Drugs Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2021-2026' report" (ResearchAndMarkets.com)
- "View source version on businesswire.com: https://www.businesswire.com/news/home/20211216005877/en/" (BusinessWire)